MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 328307 | Name: Sultiame
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sultiame, also known as Riker 594 and Ospolot, is a carbonic anhydrase inhibitor used to treat epilepsy.

Chemical Structure

Sultiame
Sultiame
CAS#61-56-3

Theoretical Analysis

MedKoo Cat#: 328307

Name: Sultiame

CAS#: 61-56-3

Chemical Formula: C10H14N2O4S2

Exact Mass: 290.0395

Molecular Weight: 290.35

Elemental Analysis: C, 41.37; H, 4.86; N, 9.65; O, 22.04; S, 22.08

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 600.00 2 Weeks
25mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Sulthiame; Riker 594; R-594; R594; R 594; Ospolot
IUPAC/Chemical Name
4-(1,1-dioxido-1,2-thiazinan-2-yl)benzenesulfonamide
InChi Key
HMHVCUVYZFYAJI-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H14N2O4S2/c11-18(15,16)10-5-3-9(4-6-10)12-7-1-2-8-17(12,13)14/h3-6H,1-2,7-8H2,(H2,11,15,16)
SMILES Code
O=S(C1=CC=C(N(CCCC2)S2(=O)=O)C=C1)(N)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 290.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Strassberger C, Hedner J, Sommermeyer D, Zou D, Grote L. The influence of diabetes on sleep-derived cardiorespiratory features of the finger pulse wave signal - The population-based SCAPIS study. Sleep Med. 2024 Oct;122:245-252. doi: 10.1016/j.sleep.2024.08.016. Epub 2024 Aug 17. PMID: 39213859. 2: Supuran CT. An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2020 Apr;16(4):297-307. doi: 10.1080/17425255.2020.1743679. Epub 2020 Mar 21. PMID: 32172611. 3: Dao K, Thoueille P, Decosterd LA, Mercier T, Guidi M, Bardinet C, Lebon S, Choong E, Castang A, Guittet C, Granier LA, Buclin T. Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers. Pharmacol Res Perspect. 2020 Feb;8(1):e00558. doi: 10.1002/prp2.558. PMID: 31990440; PMCID: PMC6986439. 4: Quade A, Thiel A, Kurth I, Holtgrewe M, Elbracht M, Beule D, Eggermann K, Scholl UI, Häusler M. Paroxysmal tonic upgaze: A heterogeneous clinical condition responsive to carbonic anhydrase inhibition. Eur J Paediatr Neurol. 2020 Mar;25:181-186. doi: 10.1016/j.ejpn.2019.11.002. Epub 2019 Nov 20. PMID: 31810576. 5: Bresnahan R, Martin-McGill KJ, Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2019 Aug 27;8(8):CD009472. doi: 10.1002/14651858.CD009472.pub4. PMID: 31453633; PMCID: PMC6710989. 6: Crettenand M, Rossetti AO, Buclin T, Winterfeld U. Antiepileptika in der Stillzeit : Wie beraten wir die Mütter? [Use of antiepileptic drugs during breastfeeding : What do we tell the mother?]. Nervenarzt. 2018 Aug;89(8):913-921. German. doi: 10.1007/s00115-018-0496-2. PMID: 29487964. 7: Gorman KM, Shahwan A. Sultiame revisited: treatment of refractory absence seizures. Epileptic Disord. 2016 Sep 1;18(3):329-33. doi: 10.1684/epd.2016.0850. PMID: 27502446. 8: Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(4):423-31. doi: 10.1517/17425255.2016.1154534. Epub 2016 Mar 3. PMID: 26878088. 9: Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2015 Oct 28;(10):CD009472. doi: 10.1002/14651858.CD009472.pub3. Update in: Cochrane Database Syst Rev. 2019 Aug 27;8:CD009472. doi: 10.1002/14651858.CD009472.pub4. PMID: 26510094. 10: Hamer HM, Dodel R, Strzelczyk A, Balzer-Geldsetzer M, Reese JP, Schöffski O, Graf W, Schwab S, Knake S, Oertel WH, Rosenow F, Kostev K. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults. J Neurol. 2012 Nov;259(11):2376-84. doi: 10.1007/s00415-012-6509-3. Epub 2012 Apr 28. PMID: 22544296. 11: Mikati MA, Shamseddine AN. Management of Landau-Kleffner syndrome. Paediatr Drugs. 2005;7(6):377-89. doi: 10.2165/00148581-200507060-00006. PMID: 16356025. 12: Maurer HH. Detection of anticonvulsants and their metabolites in urine within a "general unknown" analysis procedure using computerized gas chromatography-mass spectrometry. Arch Toxicol. 1990;64(7):554-61. doi: 10.1007/BF01971834. PMID: 1981464. 13: Pluvinage R, Delarue R. Un cas de manifestations psychiques au cours d'un traitement par le Sultiame [A case of psychic manifestations during treatment by sulthiame]. Encephale. 1965 Sep-Oct;54(5):467-9. French. PMID: 4379393. 14: Gayral L, Candebat L, Fourny L. Etude clinique et E.E.G. du Sultiame (Elisal-Ospolot) dans les différentes formes d'épilepsie et plus particuliérement dans le petit mal [Clinical and EEG study of Sulthiame (Elisal- Ospolot) in different forms of epilepsy and in petit mal]. Encephale. 1965 Sep- Oct;54(5):446-57. French. PMID: 4379392.